T cell epitope: friend or foe? Immunogenicity of biologics in context.

  title={T cell epitope: friend or foe? Immunogenicity of biologics in context.},
  author={Constanze A Weber and Preema J. Mehta and Matt T. Ardito and Lenny Moise and Bill Martin and Anne S De Groot},
  journal={Advanced drug delivery reviews},
  volume={61 11},
Like vaccines, biologic proteins can be very immunogenic for reasons including route of administration, dose frequency and the underlying antigenicity of the therapeutic protein. Because the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening. T cell epitopes are at the root of the immunogenicity issue. Through their presentation to T cells, they activate the process of anti-drug antibody development. Preclinical… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 34 extracted citations

Pharmacokinetics of Monoclonal Antibodies

CPT: pharmacometrics & systems pharmacology • 2017


Publications referenced by this paper.
Showing 1-10 of 108 references

Immune epitope database analysis resource (IEDB-AR)

Nucleic Acids Research • 2008
View 4 Excerpts
Highly Influenced

Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

The Journal of experimental medicine • 2007
View 9 Excerpts
Highly Influenced

Wildin, Rescue of the autoimmune scurfymouse by partial bonemarrow transplantation or by injectionwith T-enriched splenocytes

S. K. Smyk-Pearson, A. C. Bakke, R.S.P.K. Held
Clin. Exp. Immunol • 2003
View 9 Excerpts
Highly Influenced

Mire-Sluis, Immune responses to therapeutic proteins in humans— clinical significance, assessment and prediction

E. Koren, A.R.L.A. Zuckerman
Curr. Pharm. Biotechnol • 2002
View 2 Excerpts
Highly Influenced

Balance of Th 1 and Th 17 effector and peripheral regulatory Tcells

W. Ouyang Ghilardi
Microbes Infect . • 2009

Similar Papers

Loading similar papers…